Fig. 4
MGLL regulates macrophage activation via CB2 signal. a Relative 2-AG levels in TSMs and TAMs. Six-week-old mice were subcutaneously inoculated with MC-38 cells for 3 weeks. TSMs and TAMs were isolated for 2-AG assays. (n = 5) b Relative CB2 mRNA levels in TSMs and TAMs from 9-week-old mice inoculated with indicated subcutaneous tumors for 3 weeks. (n = 5) c Relative CB2 mRNA levels in TAMs from MC-38 tumor tissues as indicated time points after tumor injection in WT mice. (n = 5) d Relative mRNA expression of proinflammatory cytokines in the PBS- or IFNγ (10 ng ml−1) + LPS (100 ng ml−1)-treated BMDMs from the WT, TgMGLL, TgCB2 or TgMGLL+CB2 mice. (n = 5) e Relative mRNA levels of ant-inflammatory cytokines in the PBS- or IL-4 (10 ng ml−1)-treated BMDMs from the mice described in d. (n = 5) f CB2 antagonizes TLR-4 signaling. Mouse peritoneal macrophages (PMs) were primed with PBS, a CB2 inhibitor AM630 (200 nM) or a CB2 activator 2-AG (10 μM) for 2 h, and then additionally treated with PBS or LPS (500 ng ml−1) for 30 min before harvested for immunoblotting assays. The yellow values indicated the relative expression (P-JNK/JNK or P-p65/p65) according to the density. The expression value in control group for each interested protein was set as 1. Data in a–e are means ± s.e.ms. (*P < 0.05, **P < 0.01, ***P < 0.005; student’s t-test; ns not significant)
